Deepbridge Capital LLP has seeded Acorn Partners Ltd, an efficient new way of originating, developing and delivering innovation within the broader healthcare space. In collaboration with our execution partners at WeAreNova and Europe’s largest children’s hospital Alder Hey, we redefine the... Read more
Algaecytes Limited has developed a proven innovative approach to the production of Omega 3 fatty acids, which are polyunsaturated fatty acids used in numerous bodily functions, such as controlling blood clotting and building cell membranes in the brain. Associated with many health beneﬁts,... Read more
Aurio Limited has developed a patentable core technology that potentially eases the debilitating effects of tinnitus.
Tinnitus is a perception of sound in the absence of an external source. Although it is often referred to as ‘ringing in the ears’, tinnitus can also be perceived as... Read more
BeamLine Diagnostics was set up to commercialise research in to the application of infrared spectroscopy to the diagnosis of cancer. Cancer is a worldwide problem with over 14 million new diagnoses and 8 million deaths recorded in 2012 alone (according to Cancer Research UK statistics, May 2015... Read more
Care Cube Solutions Ltd (‘CCSL’) is a networked digital workflow system designed by cardiologists for users to simplify and centralise the complex tracking of patient flow in cardiology departments. In doing so, the technology seeks to safeguard patients from human error, and also assists... Read more
CO2 Estates is a leading provider of commercial and portfolio real estate energy efficiency reporting and building risk mitigation solutions. The unique SaaS cloud based software solution, ‘Carbon Estates’, focuses on commercial and portfolio real estate businesses, looking at both buildings’... Read more
Since the commencement of its development activities in 2011, Connect Childcare has developed innovative nursery management software systems for the UK childcare sector, enabling childcare staff to spend more time with the children in their care whilst simultaneously bringing parents closer to... Read more
Elasmogen Ltd is a biologics company spun out of the University of Aberdeen in Feb 2016 and has developed a validated and IP-protected ‘soloMER’ platform. ‘soloMer’ refers to employ of small proteins as a site-specific drug delivery mechanism for ophthalmology and solid tumour cancers.
... Read more
EligoChem has developed a proprietary and patentable technology that facilitates the design of highly water-soluble drugs that are absorbed well by the human body. One in fifteen known drug compounds have this combination of properties, but they are present in only one in ten thousand... Read more
eLucid mHealth is a medication technology company creating proprietary, patented automatic adherence/compliance monitoring tools as part of an integrated healthcare system.
eLucid mHealth’s solutions and devices have been specifically designed with patient feedback; they are non-invasive... Read more
PEFA (‘paced electrogram fractionation analysis’) is a unique procedure and was invented by cardiologist Dr Richard Saumarez , initially when based at St Georges Hospital, London, and subsequently developed and tested at the University of Cambridge and Papworth Hospital.
The procedure that... Read more
Filisia addresses the training, rehabilitation and access requirements of people with special education and rehabilitation needs through creative and connected technology.
Filisia estimates that there are over 150 million people globally with... Read more
Ibis Vision has developed ‘Ring of Sight’ (ROS), a unique eye test that is specifically designed for the early detection of glaucoma. Worldwide, glaucoma is the second most common cause of blindness and is caused by a build-up of pressure within the eye which in turn can damage the optic nerve... Read more
Liverpool ChiroChem (LCC) operates in the supply chain of pharmaceutical research and development (R&D), supplying specialist chemical Chiral building blocks that enable laboratory based researchers to discover and build new drug molecules. Specialist Chiral building blocks, such as... Read more
The Company has designed and developed a portable, multi-parameter, non-invasive, hand-held emergency vital signs monitor, called COREMED X. COREMED X measures electrocardiogram, heart rate, respiration rate, peripheral capillary oxygen saturation, capnography, blood pressure and... Read more
The Company was established in January 2015 by Professor Steven Ley at the University of Cambridge, following his observation that, due to industry developments such as the reduction in internal R&D spending and out-sourcing to low cost economies, access to the most creative and innovative... Read more
The Company’s primary intention is the discovery of drugs that can prevent or inhibit the progression of Parkinson’s disease (‘PD’), for which there is currently no cure. Parkure’s primary goal is to discover and co-develop drugs that stop the disease progression; the Company will also exploit... Read more
PeptiGelDesign Limited provides formulated ready-to-use and easy-to-handle hydrogels for culture dishes, multi-well plates, or cell culture inserts, used in research laboratories. PeptigelDesign believe the research services market is large and growing, estimating it to be worth c.$20bn on a... Read more
The Company was established in 2016 to exploit opportunities within the pharmaceutical sector, specifically delivering a solution to reduce manufacturing costs and increase output. To do so, the Company has established a novel technological process called ‘zero step purification’. The... Read more
Renephra Ltd is a UK based medical device development company that has developed and patented a disruptive technology that addresses the significant ongoing medical problems associated with treatment resistance of fluid overload within the body. Health issues often associated with fluid... Read more
Resonant Software Inc. has created innovative software to address human-centric inefﬁcient processes in an automated, adaptive and thus time and cost-saving way. Despite multi-billion annual investments in information technology by the ﬁnancial services industry, there remain critical... Read more
Sky Medical Technology Limited has developed the OnPulse(TM) technology platform, a technology which, at its core, has been proven to dramatically improve blood ﬂow (both volume and velocity) and elevates oxygen levels in the blood. The results indicate that the platform can be used across... Read more
The Company is developing a novel catheter system that enables patients to receive haemodialysis (‘HD’) in an improved manner. Currently, patients receiving HD must undergo a surgical procedure to create a surgical connection between an artery and a vein, the vein then acts as a ‘vascular access... Read more
Transcriptogen Ltd has developed a new approach to the treatment of cancer. The Company has developed a lead molecule, TSG1301, which has been shown to be highly effective at treating Breast and Pancreatic Cancer in human tumours that have been grafted onto mice. In addition, it appears to... Read more
Viscgo was founded in August 2015 by Dr Elizabeth Boaden and Mr Steven Bookbinder to solve the medical need for consistently and accurately measuring the viscosity of differing drinks and textured modified foods for those people being treated with differing levels of dysphagia (i.e. swallowing... Read more
VoxSmart is an award-winning mobile recording provider, addressing the global financial services compliance challenges of enabling integrated mobility and social technology within heavily regulated industries. Under UK FCA regulation, specifically COBS 11.8, all authorised and regulated... Read more
Zilico Limited has developed an innovative and patented cancer diagnostic device technology that will improve and extend current cancer screening programmes by providing accurate and objective results real-time.
The Company’s device examines the electrical impedance properties of tissues... Read more
Important Notice - Please agree before continuing
Information contained on this section of the website is not intended for retail investors. It contains details on Deepbridge services and products intended for elective professional clients only, and therefore promotion of such products and services is restricted. Therefore, you are requested to confirm that you are one of the following:
- An Investment Professional or Adviser,
- A High Net Worth Individual,
- A Sophisticated Investor, or
- A Professional Client.
- Market Counter Party
The main differences in regulatory protections afforded retails clients, compared to professional clients, include:
- Communications, including financial promotions made by us with professional clients are not subject to all of the requirements imposed by MiFID on communications with Retail clients.
- Information provisions about Deepbridge Capital LLP, its services, and remuneration that are required with respect to retail clients are not all required with respect to professional clients.
- Professional clients are not eligible complainants with respect to the Financial Ombudsman Services.
- If Deepbridge Capital LLP makes a personal recommendation or manages investments professional client in the course of MiFID or equivalent third party business, it is entitled to assume that, in relation to the products, transactions and services for which the professional client is so classified, the client has the necessary level of experience and knowledge for the purposes of suitability assessment, and where the Deepbridge Capital LLP is required to provide suitability reports to a retail client, in many cases the firm is not required to provide them to a professional client.
- With respect to non-advised services, Deepbridge Capital LLP is not required to request information or adhere to the same procedures when assessing the appropriateness of a given service or product for a professional client.
- Deepbridge Capital LLP may not be required to give warnings to the professional client if Deepbridge Capital LLP cannot determine appropriateness with respect to a given services or product.
By accessing this section of the website, you will view products and services offered by Deepbridge Capital LLP, which is directly authorised and regulated by the Financial Conduct Authority, registration number 563366. Deepbridge Capital LLP is only permitted to deal with elective professional clients, and is not permitted to engage with retail investors.